Premium
COVID‐19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors
Author(s) -
MoralesOrtega Alejandro,
García de Tena Jaime,
FrutosPérez Begoña,
JaenesBarrios Beatriz,
FarfánSedano Ana Isabel,
CanalesAlbendea Miguel Ángel,
BernalBello David
Publication year - 2021
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.33432
Subject(s) - medicine , imatinib , tyrosine kinase , immunology , imatinib mesylate , myeloid leukemia , coronavirus , crizotinib , tyrosine kinase inhibitor , cancer , virology , lung cancer , disease , covid-19 , receptor , infectious disease (medical specialty) , malignant pleural effusion
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom